Teriparatide (PTH 1-34)

Unverified protocol notes

Protocol logic check

Independent evidence

Regulatory status: approved drug label available

Storage

Store refrigerated 2-8 C except during administration; protect from light/physical damage; do not freeze; discard pen 28 days after first use.

Contraindications (limited evidence)

• Paget's disease of bone: the abnormal, accelerated bone turnover that characterizes Paget's disease creates unpredictable and potentially excessive osteoblast responses to PTH1R stimulation; absolute contraindication. Limited / unverified
• Prior radiation therapy to the skeleton: radiotherapy permanently alters bone cell biology and increases the theoretical risk of radiation-induced sarcoma development in cells stimulated by PTH1R activation; absolute contraindication per FDA label. Limited / unverified
• Open growth plates in pediatric subjects: teriparatide stimulates osteoblast proliferation at endosteal and periosteal surfaces; in subjects with active growth plates, uncontrolled stimulation of growth plate osteoprogenitor cells carries developmental and theoretical sarcoma risk. Limited / unverified
• Unexplained elevated serum alkaline phosphatase: high ALP indicates abnormal bone turnover that may reflect undiagnosed Paget's, malignancy, or other bone disease; requires investigation before teriparatide initiation. Limited / unverified
• History of primary malignancy with skeletal metastases or high risk of skeletal metastasis: PTH1R stimulation in bone with metastatic lesions may accelerate lesion growth; contraindicated. Limited / unverified
• Pre-existing hypercalcemia: teriparatide increases serum calcium via both increased bone resorption (transient) and increased renal calcium reabsorption; in subjects already hypercalcemic, further calcium elevation risks cardiac arrhythmia, nephrocalcinosis, and soft tissue calcification. Limited / unverified
• Primary hyperparathyroidism: endogenous PTH is already elevated; the mechanism mimics the continuous PTH exposure that drives bone resorption rather than formation. Limited / unverified
• Severe renal impairment (CrCl < 30 mL/min): teriparatide has not been adequately studied in subjects with severe renal failure; calcium/phosphate dysregulation risk is amplified. Limited / unverified
• Concurrent bisphosphonate therapy: bisphosphonates inhibit the osteoclast activity that PTH requires to prime osteoblast formation signaling; co-administration significantly blunts teriparatide efficacy; sequential therapy (bisphosphonate after teriparatide is discontinued) is the preferred strategy. Limited / unverified
• Pregnancy: PTH1R signaling has roles in fetal skeletal development; safety not established; avoid. Limited / unverified
• Breastfeeding: not recommended; safety data insufficient. Limited / unverified
• Prior teriparatide or abaloparatide treatment completing 24-month cumulative lifetime exposure: the 24-month maximum is a lifetime cap that applies across all cycles; exceeded use carries the osteosarcoma risk on which the FDA boxed warning is based. Limited / unverified
• Known hypersensitivity to teriparatide or any formulation excipients including metacresol (the preservative used in multidose pens). Limited / unverified

Side effects (limited evidence)

• Hypercalcemia: the most pharmacologically expected adverse effect; teriparatide transiently elevates serum calcium through bone resorption activation and renal reabsorption; symptoms include nausea, weakness, constipation, confusion, and cardiac arrhythmia at severe levels; occurs most commonly in the first months; serum calcium should be monitored 1 month after initiation. Limited / unverified
• Hypercalciuria: elevated urinary calcium excretion parallel to hypercalcemia; important to monitor in subjects with a history of nephrolithiasis. Limited / unverified
• Nausea: one of the most commonly reported adverse effects in clinical trials; onset often within 1-2 hours of injection; related to the acute PTH pulse. Limited / unverified
• Dizziness and orthostatic hypotension: particularly in the hour following injection; injecting while sitting or lying down reduces risk. Limited / unverified
• Leg cramps: most frequent musculoskeletal adverse effect in clinical trials; lower extremity muscle cramping within hours of dosing. Limited / unverified
• Headache: commonly reported in clinical trial data; transient. Limited / unverified
• Joint aches and arthralgia: reported in a subset of subjects; related to calcium flux and bone remodeling activity. Limited / unverified
• Fatigue: general; particularly in early treatment weeks as the PTH signaling establishes new bone remodeling dynamics. Limited / unverified
• Injection site reactions: pain, redness, swelling, and bruising at the subcutaneous injection site; typically mild and self-limiting. Limited / unverified
• Elevated serum uric acid: reported in clinical trials; mechanism not fully characterized; may be relevant in subjects with gout or hyperuricemia. Limited / unverified
• Osteosarcoma (theoretical in humans): carries a black box FDA warning based on rat carcinogenicity studies at supraphysiologic lifetime doses; no confirmed osteosarcoma cases attributed to teriparatide have been documented in human clinical use across over two decades of post-marketing surveillance. Limited / unverified
• Elevated alkaline phosphatase: expected pharmacological response to osteoblast activation; not an adverse event per se but a monitored laboratory marker. Limited / unverified
• Tachycardia: transient; related to acute PTH pulse and calcium flux; reported in some subjects within minutes of injection. Limited / unverified

Compatibility

The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.

Reported synergistic:

Reported contraindicated combinations:

None listed.

Sources

• https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding
• https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aae667c5-381f-4f92-93df-2ed6158d07b0